Developer docs
API playgroundTry for free, no card

Search company profiles

Leucid Bio

Full company profile

uuid0000ns5

Namestring
Leucid Bio
Legal namestring
Leucid Bio Ltd
Websiteurl
leucid.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Leucid Bio is a clinical-stage biotechnology company founded in 2014 and headquartered in London, UK, that develops next-generation CAR-T cell therapies using its proprietary Lateral CAR platform. The platform reconfigures the CAR molecule so that signalling domains are arranged in parallel across the T-cell membrane, mimicking the lateral architecture of endogenous immune receptors. Its lead clinical asset, LEU011, is an autologous lateral CAR-T therapy that targets NKG2D stress ligands (expressed on more than 80% of human tumour cells) and co-expresses the chemokine receptor CXCR2 to enhance tumour infiltration. LEU011 is being evaluated in the Phase I/IIa AERIAL trial for adults with relapsed/refractory solid tumours, including colorectal, pancreatic, mesothelioma, ovarian and breast cancer indications. The asset received an MHRA Innovation Passport in 2022 and Clinical Trial Authorisation in 2023, with the first patient dosed in May 2025 and preliminary proof-of-concept data presented at the SITC 2025 Annual Meeting.

The company is pre-revenue and operates a development-stage business model reliant on equity financing and partnership-driven manufacturing. To date Leucid Bio has raised approximately £18.7 million across two Series A tranches (£11.5M in October 2021 led by Epidarex and Vulpes, and a £7.2M Series A1 first close in February 2025 co-led by Epidarex and 2Invest AG). Clinical manufacturing is conducted via a master services agreement with Great Ormond Street Hospital's Zayed Centre for Research — the first CAR-T for solid tumours manufactured at GOSH — and through a strategic collaboration with Lonza covering its automated Cocoon Platform from clinical through commercial stages. Distribution today is limited to investigator-sponsored clinical trial sites; commercial product sales would follow regulatory approval. The science base is anchored by exclusive option rights to King's College London's broader CAR-T portfolio, built on 20+ years of research led by CSO and founder Dr John Maher.

Short descriptiontext

Leucid Bio is a London-based clinical-stage biotechnology company developing Lateral CAR-T cell therapies for solid tumours, with lead asset LEU011 — an NKG2D-targeting, CXCR2-co-expressing autologous therapy — currently in a Phase I/IIa AERIAL trial.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CAR-T cell therapy, cell therapy platform, cancer immunotherapy, autologous cell therapy, clinical-stage biotechnology
Industry1 code
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
CAR-T Cell Therapy for Solid Tumours
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1CAR-T Therapy Development and Commercialization
TypeOne Time License
Description

As a clinical-stage biotechnology company, Leucid Bio's primary revenue model is developing and commercializing proprietary CAR-T cell therapies. The company is advancing LEU011 through clinical trials with the goal of regulatory approval and commercial launch. Revenue would come from product sales upon approval.

leucid.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Leucid Bio is a clinical-stage biotechnology company developing next-generation autologous CAR-T cell therapies using its proprietary Lateral CAR platform. Its lead product, LEU011, is a lateral CAR-T therapy targeting NKG2D stress ligands (co-expressing CXCR2 to enhance tumour infiltration), currently being evaluated in the Phase I/IIa AERIAL trial in adults with relapsed/refractory solid tumours. The company intends to commercialise LEU011 and additional pipeline assets following regulatory approval, with manufacturing delivered through GOSH and Lonza's Cocoon Platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Prolonged disease-free survival demonstrated in preclinical studies comparing LEU011 to other CAR T-cell products
+1 more record
Product overview1 text field

Leucid Bio is a clinical-stage biotechnology company developing next-generation CAR-T cell therapies using its proprietary Lateral CAR Platform. The company's core product is LEU011, a lateral CAR-T therapy targeting NKG2D stress ligands, which is the lead asset in the Phase I/IIa AERIAL trial for solid tumours. The Lateral CAR Platform technology enables CAR-T cells to adopt a natural lateral membrane configuration, differentiating it from traditional linear CAR architectures and providing enhanced T-cell potency, improved tumour targeting, and reduced toxicity.

Product and service1 record
1LEU011
CategoryAutologous CAR-T cell therapy for solid tumours
Description

LEU011 is Leucid Bio's lead product candidate: an autologous lateral CAR-T cell therapy that targets NKG2D stress ligands (expressed on more than 80% of human tumour cells) and co-expresses the CXCR2 chemokine receptor to enhance tumour trafficking and infiltration. It is intended for the treatment of adults with relapsed/refractory solid tumours and is being evaluated in the Phase I/IIa AERIAL trial (ClinicalTrials.gov NCT06193902).

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-15
Description

Strategic collaboration to develop in vivo delivery of Leucid's CAR-T cell therapies using Syenex's VivoCell Platform. The partnership aims to enable precise in vivo delivery of LEU011, moving toward a simpler, potentially off-the-shelf administration route. Collaboration supports the ongoing Phase I/IIa AERIAL trial and aims to advance from proof-of-concept to IND-enabling studies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-16
Description

Manufacturing master services agreement with GOSH NHS Foundation Trust for manufacture of LEU011 at the Zayed Centre for Research into Rare Disease in Children. LEU011 is the first CAR-T candidate for solid tumours to be manufactured at GOSH. GOSH provides GMP production facilities and quality assurance services.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-12-02
Description

Strategic collaboration to utilize Lonza's Cocoon Platform for automated manufacturing of Leucid's CAR-T therapies. The partnership covers Phase I/II clinical studies through to commercial manufacturing, enabling decentralized manufacturing model for point-of-care delivery.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2014-01-01
Description

Founding partner relationship based on 20+ years of CAR-T research led by Dr John Maher. Leucid holds exclusive option rights to King's College London's broad portfolio of CAR-T assets. The company benefits from access to deep scientific, clinical and manufacturing expertise of John Maher and his academic team.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pioneer in gene-edited allogeneic CAR-T therapies with approved Casgevy. Comparable as a leading engineered T-cell therapy developer with novel receptor/genome editing approaches similar in spirit to Leucid's architectural innovation.

TypeDirect peer
Description

Clinical-stage allogeneic CAR-T developer using proprietary TALEN gene editing. Comparable engineered T-cell therapy developer with novel receptor design and genome engineering focus.

TypeDirect peer
Description

Commercial-stage cell therapy company marketing TIL therapies (lifileucel) for solid tumours. Comparable in patient-by-patient autologous cell therapy manufacturing model and solid tumour focus, with a leading commercial benchmark for the modality.

TypeDirect peer
Description

Allogeneic CAR-T developer with multiple clinical programs in oncology. Comparable as a next-generation engineered T-cell therapy developer, although Leucid is autologous while Allogene pursues an off-the-shelf model.

TypeDirect peer
Description

Clinical-stage developer of gamma delta T-cell therapies for cancer, including off-the-shelf CAR-T approaches. Comparable as an engineered immune cell therapy developer targeting solid and haematologic malignancies.

TypeDirect peer
Description

Clinical-stage CAR-T developer focused on solid and haematologic malignancies. Leucid's CEO Filippo Petti was previously CEO of Celyad, and both companies target solid tumours with engineered T-cell platforms, making them directly comparable in indication, modality, and stage.

TypeDirect peer
Description

Clinical-stage allogeneic CAR-T developer using CRISPR-based gene editing. Comparable next-generation engineered T-cell therapy developer focused on oncology with platform-based pipeline approach.

TypeDirect peer
Description

Developer of iPSC-derived NK and T-cell therapies for cancer. Comparable as a cell therapy developer pursuing off-the-shelf manufactured engineered immune cells for oncology indications.

TypeEmerging player
Description

Early clinical-stage developer of iPSC-derived allogeneic cell therapies including CAR-T and NK cells. Comparable platform-based engineered cell therapy approach, though at an earlier stage and with iPSC rather than autologous manufacturing.

TypeDirect peer
Description

Developer of engineered TCR-based cell therapies for solid tumours, including approved Tecelra. Directly comparable to Leucid as a cell therapy developer tackling the same solid tumour efficacy challenge with a novel engineered receptor architecture.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Leucid Bio

CAR-T Cell Therapy for Solid Tumoursleucid.com

Leucid Bio is a London-based clinical-stage biotechnology company developing Lateral CAR-T cell therapies for solid tumours, with lead asset LEU011 — an NKG2D-targeting, CXCR2-co-expressing autologous therapy — currently in a Phase I/IIa AERIAL trial.

What Leucid Bio does

Leucid Bio is a clinical-stage biotechnology company founded in 2014 and headquartered in London, UK, that develops next-generation CAR-T cell therapies using its proprietary Lateral CAR platform. The platform reconfigures the CAR molecule so that signalling domains are arranged in parallel across the T-cell membrane, mimicking the lateral architecture of endogenous immune receptors. Its lead clinical asset, LEU011, is an autologous lateral CAR-T therapy that targets NKG2D stress ligands (expressed on more than 80% of human tumour cells) and co-expresses the chemokine receptor CXCR2 to enhance tumour infiltration. LEU011 is being evaluated in the Phase I/IIa AERIAL trial for adults with relapsed/refractory solid tumours, including colorectal, pancreatic, mesothelioma, ovarian and breast cancer indications. The asset received an MHRA Innovation Passport in 2022 and Clinical Trial Authorisation in 2023, with the first patient dosed in May 2025 and preliminary proof-of-concept data presented at the SITC 2025 Annual Meeting.

The company is pre-revenue and operates a development-stage business model reliant on equity financing and partnership-driven manufacturing. To date Leucid Bio has raised approximately £18.7 million across two Series A tranches (£11.5M in October 2021 led by Epidarex and Vulpes, and a £7.2M Series A1 first close in February 2025 co-led by Epidarex and 2Invest AG). Clinical manufacturing is conducted via a master services agreement with Great Ormond Street Hospital's Zayed Centre for Research — the first CAR-T for solid tumours manufactured at GOSH — and through a strategic collaboration with Lonza covering its automated Cocoon Platform from clinical through commercial stages. Distribution today is limited to investigator-sponsored clinical trial sites; commercial product sales would follow regulatory approval. The science base is anchored by exclusive option rights to King's College London's broader CAR-T portfolio, built on 20+ years of research led by CSO and founder Dr John Maher.

Leucid Bio firmographics

Firmographics
Name
Leucid Bio
Legal name
Leucid Bio Ltd
Website
https://leucid.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Leucid Bio is a London-based clinical-stage biotechnology company developing Lateral CAR-T cell therapies for solid tumours, with lead asset LEU011 — an NKG2D-targeting, CXCR2-co-expressing autologous therapy — currently in a Phase I/IIa AERIAL trial.
Ownership category
akta.pro rank

Leucid Bio industry classification

Industry
Product category
CAR-T Cell Therapy for Solid Tumours
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • CAR-T cell therapy
  • Cell therapy platform
  • Cancer immunotherapy
  • Autologous cell therapy
  • Clinical-stage biotechnology

Where Leucid Bio is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Leucid Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. CAR-T Therapy Development and Commercialization: As a clinical-stage biotechnology company, Leucid Bio's primary revenue model is developing and commercializing proprietary CAR-T cell therapies. The company is advancing LEU011 through clinical trials with the goal of regulatory approval and commercial launch. Revenue would come from product sales upon approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Leucid Bio product offering

Product offering

Core offering

Leucid Bio is a clinical-stage biotechnology company developing next-generation autologous CAR-T cell therapies using its proprietary Lateral CAR platform. Its lead product, LEU011, is a lateral CAR-T therapy targeting NKG2D stress ligands (co-expressing CXCR2 to enhance tumour infiltration), currently being evaluated in the Phase I/IIa AERIAL trial in adults with relapsed/refractory solid tumours. The company intends to commercialise LEU011 and additional pipeline assets following regulatory approval, with manufacturing delivered through GOSH and Lonza's Cocoon Platform.

Product overview

Leucid Bio is a clinical-stage biotechnology company developing next-generation CAR-T cell therapies using its proprietary Lateral CAR Platform. The company's core product is LEU011, a lateral CAR-T therapy targeting NKG2D stress ligands, which is the lead asset in the Phase I/IIa AERIAL trial for solid tumours. The Lateral CAR Platform technology enables CAR-T cells to adopt a natural lateral membrane configuration, differentiating it from traditional linear CAR architectures and providing enhanced T-cell potency, improved tumour targeting, and reduced toxicity.

Differentiator

Problem solved

Functional benefit

Products and services

  • LEU011 LEU011 is Leucid Bio's lead product candidate: an autologous lateral CAR-T cell therapy that targets NKG2D stress ligands (expressed on more than 80% of human tumour cells) and co-expresses the CXCR2 chemokine receptor to enhance tumour trafficking and infiltration. It is intended for the treatment of adults with relapsed/refractory solid tumours and is being evaluated in the Phase I/IIa AERIAL trial (ClinicalTrials.gov NCT06193902).

Quantifiable outcome

  • Prolonged disease-free survival demonstrated in preclinical studies comparing LEU011 to other CAR T-cell products
  • +1 more outcomes

Companies that use Leucid Bio

Customer profile

Segments1 record

Ideal customer profiles2 records

Leucid Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Leucid Bio partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • SyenexcoreTechnology or Integration · 15 December 2025Strategic collaboration to develop in vivo delivery of Leucid's CAR-T cell therapies using Syenex's VivoCell Platform. The partnership aims to enable precise in vivo delivery of LEU011, moving toward a simpler, potentially off-the-shelf administration route. Collaboration supports the ongoing Phase I/IIa AERIAL trial and aims to advance from proof-of-concept to IND-enabling studies.
  • Great Ormond Street Hospital (GOSH)coreStrategic or Co-development Partner · 16 March 2023Manufacturing master services agreement with GOSH NHS Foundation Trust for manufacture of LEU011 at the Zayed Centre for Research into Rare Disease in Children. LEU011 is the first CAR-T candidate for solid tumours to be manufactured at GOSH. GOSH provides GMP production facilities and quality assurance services.
  • LonzacoreStrategic or Co-development Partner · 2 December 2021Strategic collaboration to utilize Lonza's Cocoon Platform for automated manufacturing of Leucid's CAR-T therapies. The partnership covers Phase I/II clinical studies through to commercial manufacturing, enabling decentralized manufacturing model for point-of-care delivery.
  • King's College LondoncoreTechnology or Integration · 1 January 2014Founding partner relationship based on 20+ years of CAR-T research led by Dr John Maher. Leucid holds exclusive option rights to King's College London's broad portfolio of CAR-T assets. The company benefits from access to deep scientific, clinical and manufacturing expertise of John Maher and his academic team.

Scale indicators3 records

Recent moves9 records

Expansion highlights5 records

Leucid Bio competitors and assessment

Company assessment

Direct peers

  • CRISPR Therapeutics: Pioneer in gene-edited allogeneic CAR-T therapies with approved Casgevy. Comparable as a leading engineered T-cell therapy developer with novel receptor/genome editing approaches similar in spirit to Leucid's architectural innovation.
  • Cellectis: Clinical-stage allogeneic CAR-T developer using proprietary TALEN gene editing. Comparable engineered T-cell therapy developer with novel receptor design and genome engineering focus.
  • Iovance Biotherapeutics: Commercial-stage cell therapy company marketing TIL therapies (lifileucel) for solid tumours. Comparable in patient-by-patient autologous cell therapy manufacturing model and solid tumour focus, with a leading commercial benchmark for the modality.
  • Allogene Therapeutics: Allogeneic CAR-T developer with multiple clinical programs in oncology. Comparable as a next-generation engineered T-cell therapy developer, although Leucid is autologous while Allogene pursues an off-the-shelf model.
  • Adicet Bio: Clinical-stage developer of gamma delta T-cell therapies for cancer, including off-the-shelf CAR-T approaches. Comparable as an engineered immune cell therapy developer targeting solid and haematologic malignancies.
  • Celyad Oncology: Clinical-stage CAR-T developer focused on solid and haematologic malignancies. Leucid's CEO Filippo Petti was previously CEO of Celyad, and both companies target solid tumours with engineered T-cell platforms, making them directly comparable in indication, modality, and stage.
  • Caribou Biosciences: Clinical-stage allogeneic CAR-T developer using CRISPR-based gene editing. Comparable next-generation engineered T-cell therapy developer focused on oncology with platform-based pipeline approach.
  • Fate Therapeutics: Developer of iPSC-derived NK and T-cell therapies for cancer. Comparable as a cell therapy developer pursuing off-the-shelf manufactured engineered immune cells for oncology indications.
  • Adaptimmune Therapeutics: Developer of engineered TCR-based cell therapies for solid tumours, including approved Tecelra. Directly comparable to Leucid as a cell therapy developer tackling the same solid tumour efficacy challenge with a novel engineered receptor architecture.

Emerging players

  • Century Therapeutics: Early clinical-stage developer of iPSC-derived allogeneic cell therapies including CAR-T and NK cells. Comparable platform-based engineered cell therapy approach, though at an earlier stage and with iPSC rather than autologous manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Leucid Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Leucid Bio leadership team

Management profile

Number of profiles

Profiles11 records

Leucid Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Leucid Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Leucid Bio

What does Leucid Bio do?

Leucid Bio is a clinical-stage biotechnology company developing next-generation autologous CAR-T cell therapies using its proprietary Lateral CAR platform. Its lead product, LEU011, is a lateral CAR-T therapy targeting NKG2D stress ligands (co-expressing CXCR2 to enhance tumour infiltration), currently being evaluated in the Phase I/IIa AERIAL trial in adults with relapsed/refractory solid tumours. The company intends to commercialise LEU011 and additional pipeline assets following regulatory approval, with manufacturing delivered through GOSH and Lonza's Cocoon Platform.

Is Leucid Bio a public or private company?

Leucid Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Leucid Bio founded?

Leucid Bio was founded in 2014. It employs 11 to 50 people.

Where is Leucid Bio based?

Leucid Bio is headquartered in London, United Kingdom, in the Europe region.

How does Leucid Bio make money?

One revenue line is on record: CAR-T Therapy Development and Commercialization.

Who are Leucid Bio's main competitors?

Direct peers on record are CRISPR Therapeutics, Cellectis, Iovance Biotherapeutics, Allogene Therapeutics, Adicet Bio, Celyad Oncology, Caribou Biosciences, Fate Therapeutics and Adaptimmune Therapeutics. Century Therapeutics is listed as an emerging player.

Does Leucid Bio have an API?

No public API is recorded for Leucid Bio.

What industry is Leucid Bio in?

Leucid Bio's product category is CAR-T Cell Therapy for Solid Tumours. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioProcess InternationalLeucid Bio and Syenex team up to advance CAR-T administrationBiotechnology company Leucid Bio announced a strategic collaboration with gene therapy platform firm Syenex to gain access to Syenex's VivoCell Platform for in vivo delivery of Leucid's CAR-T cell assets, including LEU011 which is under development for solid tumors. The platform enables generation of CAR-T cells within the body, bypassing traditional ex vivo processing and logistics challenges associated with current CAR-T administration. Leucid will continue clinically validating LEU011 in the ongoing Phase I/IIa AERIAL trial, which has shown preliminary evidence of good tolerability and disease control in patients with relapsed/refractory solid tumors.PharmiWeb.comLeucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell EngineeringLeucid Bio and Syenex announced a strategic collaboration to use Syenex's VivoCell Platform for in vivo delivery of Leucid's CAR-T therapy LEU011 in treating solid tumours. The non-exclusive agreement enables CAR-T cell engineering directly within the body, eliminating the need for complex ex vivo cell processing and logistics. The collaboration aims to accelerate Leucid's in vivo programme toward IND-enabling studies while the company continues its ongoing Phase I/IIa AERIAL trial for LEU011.PharmiWeb.comLeucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell EngineeringLeucid Bio and Syenex have announced a strategic collaboration to enable in vivo delivery of Leucid’s CAR-T therapy candidate LEU011 using Syenex’s VivoCell Platform, with the goal of transforming conventional ex vivo CAR-T processing into a simpler, potentially off-the-shelf administration approach. The collaboration aims to accelerate Leucid’s in vivo program from in vitro proof-of-concept to IND-enabling studies while supporting the ongoing Phase I/IIa AERIAL trial of LEU011 in patients with relapsed/refractory solid tumours. LEU011 has demonstrated good tolerability and functional activity in early trial data, and the partnership is expected to unlock the therapeutic potential of Leucid’s lateral CAR-T platform.PR NewswireLeucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell EngineeringLeucid Bio and Syenex announced a strategic collaboration to use Syenex's VivoCell Platform for precise in vivo delivery of Leucid's CAR-T therapy LEU011 targeting solid tumours. The partnership aims to eliminate the need for complex ex vivo cell processing by enabling direct in vivo CAR-T cell engineering, accelerating the programme from in vitro proof-of-concept toward IND-enabling studies. LEU011 is currently being evaluated in the ongoing Phase I/IIa AERIAL trial for relapsed/refractory solid tumours.PharmiWeb.comLeucid Bio Provides Update on Phase I/IIa AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid TumoursLeucid Bio announced preliminary results from its Phase I/IIa AERIAL trial evaluating LEU011, a CAR-T therapy for relapsed/refractory solid tumours, establishing proof-of-concept through demonstrated pharmacokinetic and pharmacodynamic profiles, tumour infiltration by LEU011 cells, and disease control in multiple patients at the lowest dose evaluated. The therapy has been generally well tolerated to date, with dose-escalation continuing as planned. Additional trial data is anticipated during the first half of 2026, with results presented at the SITC 2025 Annual Meeting.PR NewswireLeucid Bio Provides Update on Phase I/IIa AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid TumoursLeucid Bio announced preliminary data from its Phase I/IIa AERIAL trial showing proof-of-concept for LEU011, a CAR-T cell therapy targeting solid tumours, with the treatment being generally well tolerated and disease control observed in multiple patients at the lowest dose evaluated. The dose-escalation segment of the trial continues as planned, with additional data anticipated during the first half of 2026. The findings were presented at the Society for Immunotherapy of Cancer Annual Meeting 2025.PharmiWeb.comLeucid Bio Provides Update on Phase I/IIa AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid TumoursLeucid Bio announced preliminary results from its ongoing Phase I/IIa AERIAL trial evaluating LEU011, a lateral CAR-T therapy for relapsed/refractory solid tumours. The trial established proof-of-concept with LEU011 demonstrating encouraging pharmacokinetic and pharmacodynamic profiles, tumour infiltration by LEU011 cells, and disease control in multiple patients at the lowest dose evaluated, while treatment was generally well tolerated. Dose-escalation continues as planned with additional data anticipated in the first half of 2026.PR NewswireLeucid Bio to Participate in Morgan Stanley 23rd Annual Global Healthcare ConferenceLeucid Bio, a biotechnology company, announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York, scheduled for September 8, 2025.